Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

Amanda Mocroft, Peter Reiss, Ole Kirk, Cristina Mussini, Enrico Girardi, Philippe Morlat, Christoph Stephan, Stephane De Wit, Katja Doerholt, Jade Ghosn, Heiner C Bucher, Jens D Lundgren, Genevieve Chene, Jose M Miro, Hansjakob Furrer, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

    93 Citationer (Scopus)

    Abstract

    Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
    OriginalsprogEngelsk
    TidsskriftClinical Infectious Diseases
    Vol/bind51
    Udgave nummer5
    Sider (fra-til)611-9
    Antal sider9
    ISSN1058-4838
    DOI
    StatusUdgivet - 1 sep. 2010

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count'. Sammen danner de et unikt fingeraftryk.

    Citationsformater